Gamma-delta T cells to prevent leukemia relapse after transplant
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if a special type of immune cell called gamma-delta T cells can help prevent acute myeloid leukemia from coming back after a stem cell transplant. It is for people with high-risk features who have recently had a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have been diagnosed with acute myeloid leukemia (AML) and had a stem cell transplant within the last 30 days (plus or minus 5 days).
- Your leukemia must have one or more high-risk signs, like not responding to treatment, having very high white blood cells, or signs of disease before transplant.
- You need to be recovered enough from past treatments, with manageable side effects.
- Your major organs (like liver, kidneys, heart, and lungs) must be working well enough based on recent tests.
- You cannot have severe graft-versus-host disease (GVHD), other cancers (unless treated), or serious heart, lung, or brain conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a specific transplant method using a half-matched donor to treat high-risk acute myeloid leukemia (AML), a type of blood cancer. It aims to reduce complications and improve outcomes for patients who have not responded to other treatments.
This trial tests a type of immune cell called gamma-delta T cells in people with acute myeloid leukemia who still have minimal residual disease after a stem cell transplant. The goal is to see if these cells can clear the remaining leukemia cells safely and effectively.
This early-phase study tests giving a special immune-cell treatment after an allogeneic (donor) stem cell transplant, plus a medication given after transplant to help the new immune system work better. It may help prevent or treat cancer returning after transplant.
This trial tests a special transplant approach for people with high-risk acute leukemia. It uses a stronger dose of radiation before transplant, followed by an infusion of immune cells (regulatory and conventional T cells) to help the transplant work better and fight the leukemia.
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
This trial tests a new treatment called NCR300 to see if it can prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. It may help people who are at high risk of relapse.
Hear when a new High Risk Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.